Tinzaparin sodium

File:Tinzaparin.svg

Tinzaparin.svg

Tinzaparin sodium is a low molecular weight heparin (LMWH) used as an anticoagulant to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used in the treatment of acute coronary syndromes (ACS) and for the prevention of clotting in the extracorporeal circuit during hemodialysis.

Mechanism of Action

Tinzaparin sodium works by inhibiting factor Xa and thrombin (factor IIa) in the coagulation cascade. This inhibition prevents the formation of fibrin clots, thereby reducing the risk of thrombus formation. Tinzaparin has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin, which contributes to its anticoagulant effect.

Indications

Tinzaparin sodium is indicated for:

• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)
• Prevention of DVT and PE in patients undergoing surgery
• Treatment of acute coronary syndromes (ACS)
• Prevention of clotting in the extracorporeal circuit during hemodialysis

Administration

Tinzaparin sodium is administered via subcutaneous injection. The dosage and duration of treatment depend on the specific condition being treated and the patient's response to therapy. Regular monitoring of anti-Xa levels may be required to ensure therapeutic efficacy and safety.

Side Effects

Common side effects of tinzaparin sodium include:

• Bleeding
• Thrombocytopenia
• Injection site reactions
• Allergic reactions

Serious side effects may include:

• Severe bleeding
• Heparin-induced thrombocytopenia (HIT)
• Osteoporosis with long-term use

Contraindications

Tinzaparin sodium is contraindicated in patients with:

• Active major bleeding
• History of heparin-induced thrombocytopenia (HIT)
• Severe thrombocytopenia
• Hypersensitivity to tinzaparin or any of its components

Monitoring

Patients receiving tinzaparin sodium should be monitored for signs of bleeding and other adverse effects. Regular blood tests, including complete blood count (CBC) and anti-Xa levels, may be necessary to ensure safe and effective treatment.

Comparison with Other Anticoagulants

Tinzaparin sodium is one of several low molecular weight heparins available, including enoxaparin and dalteparin. Compared to unfractionated heparin, LMWHs like tinzaparin have a more predictable anticoagulant response, longer half-life, and lower risk of heparin-induced thrombocytopenia (HIT).

See Also

• Heparin
• Low molecular weight heparin
• Deep vein thrombosis
• Pulmonary embolism
• Acute coronary syndrome
• Heparin-induced thrombocytopenia